BMO Capital Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $30
BMO Capital Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $30 富途牛牛
Covered in this story
What has happened since
- Pfizer is up 0.6% since this was published, 48 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
BMO Capital Markets’s $30 target on $PFE is on the record and being tracked to Aug 2027 (12-month default), scored on the close that day.
BMO Capital Markets’s track record →Analyst targets on Pfizer
- HSBC: $23.7 → $28 by Jul 2027 · Hold via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $PFE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Pfizer →Dalsna Finance is currently tracking 47 stories mentioning Pfizer, the earliest published 18 Jun 2026.
Summary aggregated from 富途牛牛's public RSS feed. The full reporting belongs to 富途牛牛 — please read it on their site.